Information Provided By:
Fly News Breaks for January 20, 2017
JAZZ
Jan 20, 2017 | 08:17 EDT
Leerink analyst Jason Gerberry hosted a call with two specialists in drug patents and Hatch Waxman regulatory issues, who said that while Jazz Pharmaceuticals' longest-lived Xyrem patents are not impenetrable, recent FDA updates are a "favorable catalyst" for patent settlement that would extend franchise exclusivity 2-3 years beyond the buy-side consensus. The analyst reiterates an Outperform rating and $182 price target on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ